NEW YORK (GenomeWeb) – Interpace Diagnostics announced today that it has closed a $3.9 million public offering of its common stock.
The previously announced offering included the sale of 1.2 million shares of Interpace common stock at $3 per share, as well as 108,000 additional shares related to the full exercise of an over-allotment option granted to the underwriters of the transaction.
Interpace had said it intends to use the proceeds of the offering for working capital, to repay debt and other liabilities, and for general corporate purposes.
Maxim Group acted as sole book-running manager for the offering. Roth Capital Partners served as financial advisor.